Articles from Dispatch Bio

Dispatch Bio, a biotechnology company developing a universal treatment for solid tumors, today announced preclinical data supporting its first therapeutic program planned to enter the clinic, DISP-10, and its first-in-class Flare platform, at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting.

Dispatch Bio, a biotech company engineering a universal treatment across solid tumors leveraging its first-in-class Flare platform, today announced a clinical supply and collaboration agreement with Bristol Myers Squibb (“BMS”) to support the development of Dispatch’s DISP-10 program. Under the agreement, BMS will provide idecabtagene vicleucel (ide-cel), a BCMA-directed CAR T therapy, for use in Dispatch’s first U.S. Phase 1 trial, expected to initiate in 2026.

Dispatch Bio, a biotech company engineering a universal treatment across solid tumors, leveraging its first-in-class Flare platform, today announced two upcoming presentations at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, taking place in National Harbor, Md., Nov. 5-9, 2025.

Dispatch Bio, a biotech company engineering a universal treatment across solid tumors, leveraging its first-in-class Flare platform, today announced the appointment of Mauro Avanzi, M.D., Ph.D., as Chief Medical Officer. Dr. Avanzi is a Board-certified hematologist/oncologist, a physician-scientist and an immunologist with more than 15 years of clinical development experience across early and late stages. He will lead Dispatch’s clinical team to advance Dispatch’s growing pipeline of therapeutic candidates, with first-in-human studies planned for 2026.

Dispatch Bio announced its official launch today, with a mission to engineer a universal treatment across solid tumors, which represent approximately 90% of cancers worldwide.